Literature DB >> 2569571

Continuous infusion of ceftazidime in cystic fibrosis.

J Kuzemko, C Crawford.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2569571     DOI： 10.1016/s0140-6736(89)90561-8

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  13 in total

Review 1.  Continuous infusion of beta-lactam antibiotics.

Authors:  W A Craig; S C Ebert
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

2.  In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Authors:  M Manduru; L B Mihm; R L White; L V Friedrich; P A Flume; J A Bosso
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

Review 3.  Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory.

Authors:  Mordechai Grupper; Joseph L Kuti; David P Nicolau
Journal:  Clin Microbiol Rev       Date:  2016-10       Impact factor: 26.132

4.  Continuous-infusion antipseudomonal Beta-lactam therapy in patients with cystic fibrosis.

Authors:  William A Prescott; Allison E Gentile; Jerod L Nagel; Rebecca S Pettit
Journal:  P T       Date:  2011-11

5.  High-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients.

Authors:  Brad Moriyama; Stacey A Henning; Richard Childs; Steven M Holland; Victoria L Anderson; John C Morris; Wyndham H Wilson; George L Drusano; Thomas J Walsh
Journal:  Ann Pharmacother       Date:  2010-04-06       Impact factor: 3.154

6.  Pharmacokinetics of Continuous Infusion Beta-lactams in the Treatment of Acute Pulmonary Exacerbations in Adult Patients With Cystic Fibrosis.

Authors:  Lisa T Hong; Theodore G Liou; Rishi Deka; Jordan B King; Vanessa Stevens; David C Young
Journal:  Chest       Date:  2018-06-13       Impact factor: 9.410

7.  Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections.

Authors:  A S Benko; D M Cappelletty; J A Kruse; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

Review 8.  Continuous infusion of beta-lactam antibiotics.

Authors:  A P MacGowan; K E Bowker
Journal:  Clin Pharmacokinet       Date:  1998-11       Impact factor: 6.447

Review 9.  Impact of dosage schedule of antibiotics on the treatment of serious infections.

Authors:  I A Bakker-Woudenberg; R Roosendaal
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

10.  Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis.

Authors:  J Riethmueller; S Junge; T W Schroeter; K Kuemmerer; P Franke; M Ballmann; A Claass; S Broemme; R Jeschke; A Hebestreit; D Staab; K Koetz; G Doering; M Stern
Journal:  Infection       Date:  2009-09-05       Impact factor: 3.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.